Cachexia in children with chronic kidney disease: challenges in diagnosis and treatment.
Although cachexia is highly prevalent in adult patients with chronic kidney disease (CKD), it is understudied and less well characterized in children. Recent evidence suggests that cachexia is also prevalent in children with CKD but presents challenges in diagnosis and treatment.



A study from the CKD in children cohort showed that CKD cachexia or protein-energy wasting, using modified pediatric diagnostic criteria, such as lack of expected weight gain instead of weight loss and BMI for height age, had a prevalence of 7-20%. When growth indices such as height SD score (SDS)/height velocity SDS was included in the criteria, cachexia or PEW correlated with the morbidity outcome of increased hospitalization risk in children with CKD. Conversely, aggressive nutritional supplementation in children with advanced CKD, with nasogastric or gastric tube feeding, led to prevalence of obesity over that of cachexia. Body habitus of underweight and obesity have been shown to be associated with the worst clinical outcomes in both adults and children with CKD.



Optimal nutritional therapy remains the mainstay of treatment of cachexia in CKD children with therapeutic goals of maintaining BMI as well as linear growth within the normal range.
Division of Pediatric Nephrology, University of California, San Diego; Rady Children's Hospital, San Diego, California, USA.
Robert H
RH
Mak
D000293:Adolescent; D019167:Appetite Stimulants / Q000627:therapeutic use; D015992:Body Mass Index; D002100:Cachexia / Q000175:diagnosis / Q000178:diet therapy* / Q000188:drug therapy / Q000209:etiology*; D002648:Child; D054439:Ghrelin / Q000627:therapeutic use; D006128:Growth / Q000502:physiology; D006801:Humans; D018529:Nutritional Support / Q000379:methods*; D015995:Prevalence; D051436:Renal Insufficiency, Chronic / Q000150:complications*
D019167:Appetite Stimulants; D054439:Ghrelin